RG13022 demonstrated rapid biexponential elimination from plasma with a terminal half-life of 50.4 min. RG13022 plasma concentrations were less than 1 microM by 20 min post injection.
However, despite decreased renal elimination, the plasma PCT clearance rate correlated only weakly with renal dysfunction, and thus interpretation of plasma PCT levels should not be confounded by this condition.
Finally, regarding the elimination of plasma Aβ, animal models have implicated the liver as the major organ responsible for the clearance of Aβ from plasma [ 24], followed by renal clearance [ 25].
The interpretation of results also is hampered by unpredictable renal and hepatic elimination of plasma myoglobin, and published correlation with the degree of myoglobinemia is poor.
Initial pharmacokinetic evaluation in mice of novel AG1478 formulations in a beta-cyclodextrin (Captisol®) showed monoexponential elimination from plasma (half-life 30 min) following subcutaneous administration.
The aims of therapeutic apheresis are: a) extraction and elimination from plasma of disease mediators or disease carrying media, b) replacement of deficient factors, and c) improvement of the function of the reticuloendothelial systems and certain inflammatory mediators.
The pharmacokinetics of F-florbetaben was characterized by a rapid elimination from plasma.
Elimination in plasma was best described by a monoexponential equation with an elimination half-life of 96 ± 16 minutes.
Elimination of plasma lipids and proteins was in the normal range for DFPP by the materials used [ 18].
GST-zeta depletion slowed DCA elimination from plasma, allowing kinetic analysis of doses as low as 0.05 mg/kg.
